AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24124331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 0.5 kcal/min
Number of subjects: 15
Study 24124331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 1.0 kcal/min
Number of subjects: 15
Study 24124331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 1.5 kcal/min
Number of subjects: 15
Study 21104305 — intervention group
Group type: COMPARATOR
Intervention: Spanish-speaking defendant
Number of subjects: 142
Study 21104305 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking defendant
Number of subjects: 142
Study 21104305 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived logistical barriers to CST evaluation
Number of subjects: 142
Study 19246440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarette
Number of subjects: 0
Study 19246440 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 0
Study 17472862 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical barriers to contraception
Number of subjects: 0
Study 14971978 — intervention group
Group type: EXPERIMENTAL
Intervention: Land plyometric training
Number of subjects: 32
Study 14971978 — intervention group
Group type: COMPARATOR
Intervention: Aquatic plyometric training
Number of subjects: 32
Study 11701674 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of GH (0.05 mg/kg x d)
Number of subjects: 198
Study 11701674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of GH (0.025 mg/kg x d)
Number of subjects: 198
Study 11701674 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 198
Study 9156352 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-52458 (200 mg)
Number of subjects: 16
Study 9156352 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-52458 (100 mg or more)
Number of subjects: 16
Study 9156352 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-52458 (10-150 mg)
Number of subjects: 16
Study 9156352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8251893 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + low-dose Ara-C
Number of subjects: 237
Study 8251893 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 237
Study 3102779 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg parenterally
Number of subjects: 70
Study 3102779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3102779 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide in diabetic patients
Number of subjects: 70
Study 3102779 — intervention group
Group type: COMPARATOR
Intervention: Placebo in diabetic patients
Number of subjects: 70
Study 31099331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash intervention for preventing oropharyngeal gonorrhoea
Number of subjects: 0
Study 31099331 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28449228 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA steady (2-2.5 mg/kg/day)
Number of subjects: 81
Study 28449228 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA down (1-1.25 mg/kg/day)
Number of subjects: 81
Study 28449228 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA stopped
Number of subjects: 81
Study 28449228 — intervention group
Group type: COMPARATOR
Intervention: AZA steady
Number of subjects: 81
Study 28449228 — intervention group
Group type: COMPARATOR
Intervention: AZA down
Number of subjects: 81
Study 25617252 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF‐CBT
Number of subjects: 69
Study 25617252 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 69
Study 23582510 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 608
Study 23582510 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 608
Study 21484416 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitor (SRI) medication
Number of subjects: 124
Study 19901863 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 141
Study 16570006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacro/Siro
Number of subjects: 150
Study 16570006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacro/MMF
Number of subjects: 150
Study 16570006 — intervention group
Group type: COMPARATOR
Intervention: CsA/Siro
Number of subjects: 150
Study 15214181 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxitherapy (NHT) combined with standard treatment in the basic group of 32 patients.
Number of subjects: 52
Study 15214181 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only in the control group of 20 patients.
Number of subjects: 52
Study 14670703 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10969225 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 50
Study 10969225 — intervention group
Group type: COMPARATOR
Intervention: Triethanolamine polypeptide
Number of subjects: 50
Study 10969225 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate sodium (in children aged 5 or less)
Number of subjects: 50
Study 10969225 — intervention group
Group type: COMPARATOR
Intervention: Triethanolamine polypeptide (in children aged 5 or less)
Number of subjects: 50
Study 8695078 — intervention group
Group type: EXPERIMENTAL
Intervention: PCINA for 4 hours followed by 5 hours of ward‐provided pain therapy (Group 1; n = 10)
Number of subjects: 20
Study 8695078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward‐provided pain therapy for 5 hours followed by 4 hours of PCINA (Group 2; n = 10)
Number of subjects: 20
Study 8695078 — intervention group
Group type: EXPERIMENTAL
Intervention: PCINA
Number of subjects: 20
Study 8695078 — intervention group
Group type: COMPARATOR
Intervention: Ward‐provided pain therapy
Number of subjects: 20
Study 1355745 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 24
Study 1355745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6369524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (3.5 mg/kg/day)
Number of subjects: 0
Study 6369524 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methylprednisolone (1.0 mg/kg/day)
Number of subjects: 0
Study 30269963 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive resistive monopolar radiofrequency (CRMRF) treatment
Number of subjects: 45
Study 30269963 — intervention group
Group type: COMPARATOR
Intervention: Sham-CRMRF treatment
Number of subjects: 45
Study 30269963 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 45
Study 30402840 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 62
Study 30402840 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 62
Study 26695724 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron (100 mg), folic acid (500 mcg) and placebo for 26 weeks (Group A)
Number of subjects: 446
Study 26695724 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron (100 mg), folic acid (500 mcg) and cyanocobalamin (500 mcg for 6 weeks and 15 mcg for 20 weeks) for 26 weeks (Group B)
Number of subjects: 446
Study 23761326 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D3 daily
Number of subjects: 198
Study 23761326 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D3 daily
Number of subjects: 198
Study 23761326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU of vitamin D3 daily
Number of subjects: 198
Study 23761326 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 IU of vitamin D3 daily
Number of subjects: 198
Study 23761326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 23107038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise training
Number of subjects: 64
Study 20163197 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 2 g + laropiprant (LRPT) 40 mg
Number of subjects: 0
Study 20163197 — intervention group
Group type: COMPARATOR
Intervention: Extended-release niacin (ERN) 2 g
Number of subjects: 0
Study 20163197 — intervention group
Group type: COMPARATOR
Intervention: Laropiprant (LRPT) alone
Number of subjects: 0
Study 20163197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17631681 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulphadoxine/pyrimethamine (AS/SP)
Number of subjects: 160
Study 17631681 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 160
Study 15660039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lead ST resolution (STR)
Number of subjects: 3030
Study 15660039 — intervention group
Group type: COMPARATOR
Intervention: Sum STR
Number of subjects: 3030
Study 11848169 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (GB; 2-8 mg at 11 PM, n = 17)
Number of subjects: 34
Study 11848169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 34
Study 10448876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation (two doses)
Number of subjects: 474
Study 10448876 — intervention group
Group type: COMPARATOR
Intervention: Clinician's impression (no progression)
Number of subjects: 474
Study 10448876 — intervention group
Group type: COMPARATOR
Intervention: Clinician's impression (progression)
Number of subjects: 474
Study 8543717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief prevention program (BP) consisting of 4 sessions of cognitive-behavioral therapy (CBT)
Number of subjects: 20
Study 8543717 — intervention group
Group type: COMPARATOR
Intervention: Assessment control (AC)
Number of subjects: 20
Study 8543717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief prevention program (BP)
Number of subjects: 20
Study 2337214 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution prewarmed to 37 degrees C
Number of subjects: 24
Study 2337214 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic solution at room temperature
Number of subjects: 24
Study 463893 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of lidocaine infusion (Group 1)
Number of subjects: 29
Study 463893 — intervention group
Group type: COMPARATOR
Intervention: Gradual tapering of lidocaine infusion over a three-hour period (Group 2)
Number of subjects: 29
Study 463893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for 36 hours or less
Number of subjects: 29
Study 463893 — intervention group
Group type: COMPARATOR
Intervention: Comparison of abrupt cessation versus three-hour tapering of lidocaine infusion
Number of subjects: 29
Study 31721601 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella-zoster virus (VZV) vaccine (ZVIN)
Number of subjects: 155
Study 31721601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 30935872 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery with faster-acting insulin aspart
Number of subjects: 43
Study 30935872 — intervention group
Group type: COMPARATOR
Intervention: Conventional subcutaneous insulin therapy (control group)
Number of subjects: 43
Study 28611343 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN 180 mcg weekly for 12 months (add-on therapy)
Number of subjects: 48
Study 28611343 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir 300 mg orally daily (monotherapy)
Number of subjects: 48
Study 24985348 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 56
Study 24985348 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated enamel slabs
Number of subjects: 56
Study 24985348 — intervention group
Group type: COMPARATOR
Intervention: Deionized water immersion
Number of subjects: 56
Study 24985348 — intervention group
Group type: COMPARATOR
Intervention: Citric acid immersion
Number of subjects: 56
Study 22981698 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session brief intervention (S1)
Number of subjects: 202
Study 21317934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin 250 mg daily for 12 weeks
Number of subjects: 22
Study 21317934 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 22
Study 19485594 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 731
Study 19485594 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 731
Study 17048231 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased serum EGFR levels
Number of subjects: 535
Study 17048231 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased serum EGFR and normal serum HER-2
Number of subjects: 535
Study 17048231 — intervention group
Group type: COMPARATOR
Intervention: Normal serum EGFR and HER-2
Number of subjects: 535
Study 12735919 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formulations of low calorie carbonated orange drinks
Number of subjects: 15
Study 12735919 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional diet products and water)
Number of subjects: 15
Study 11549101 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-cholesterol-labeled AmBisome (2 mg/kg, 1 microgCi/kg)
Number of subjects: 5
Study 11549101 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-cholesterol-labeled AmBisome
Number of subjects: 5
Study 10165099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral smoking cessation program
Number of subjects: 93
Study 10165099 — intervention group
Group type: COMPARATOR
Intervention: Self-help control condition
Number of subjects: 93
Study 7879710 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole herpes simplex vaccines
Number of subjects: 15000
Study 2849775 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg/70 kg
Number of subjects: 41
Study 2849775 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.2 mg/70 kg
Number of subjects: 41
Study 2849775 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.25 mg/70 kg
Number of subjects: 41
Study 2849775 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study 1520049 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials (monograph, pamphlet, and audiotape) provided to physicians before the simulated patient visit.
Number of subjects: 232
Study 1520049 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the study risk assessment questionnaire during the simulated patient visit.
Number of subjects: 232
Study 1520049 — intervention group
Group type: EXPERIMENTAL
Intervention: General patient interaction measures.
Number of subjects: 232
Study 1520049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of physicians during the simulated patient visit.
Number of subjects: 232
Study 603271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (5000 units two hours before operation and 5000 units every 12 hours following operation for five days)
Number of subjects: 175
Study 603271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin postoperatively only
Number of subjects: 175
Study 603271 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 31655314 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue massage
Number of subjects: 619
Study 31655314 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised strengthening and stretching exercises
Number of subjects: 619
Study 31655314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (exercise followed by massage)
Number of subjects: 619
Study 31655314 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay active
Number of subjects: 619
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients with CD4 count <200 cells/ul
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients with CD4 count 200-350 cells/ul
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients living with HIV ≥9 years
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients living with HIV 5-8 years
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients infected with intestinal parasites
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients with BMI <18.5 kg/m2
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients with BMI 18.5-25 kg/m2
Number of subjects: 411
Study 31596865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients who are HAART naïve
Number of subjects: 411
Study 28218556 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical protocol A (Trial 1)
Number of subjects: 448
Study 28218556 — intervention group
Group type: COMPARATOR
Intervention: Surgical protocol A (Trial 2)
Number of subjects: 448
Study 28218556 — intervention group
Group type: COMPARATOR
Intervention: Surgical protocol A (Trial 3)
Number of subjects: 448
Study 28218556 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (overall performance)
Number of subjects: 448
Study 25561359 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 - Training focused on ball handling, balance, and manual dexterity
Number of subjects: 43
Study 25561359 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 - Training in sports without a specific focus
Number of subjects: 43
Study 25561359 — intervention group
Group type: COMPARATOR
Intervention: CG - Wait-list control group, no intervention
Number of subjects: 43
Study 23786558 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ketamine (0.2 mg/kg/hour)
Number of subjects: 64
Study 23786558 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone PCA and saline (Control)
Number of subjects: 64
Study 23786558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Control)
Number of subjects: 64
Study 21341148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg
Number of subjects: 50
Study 21341148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19843807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 60
Study 19843807 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation (NS)
Number of subjects: 60
Study 17524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 10
Study 17524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerine juice
Number of subjects: 10
Study 17524940 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 12638394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after overnight fast
Number of subjects: 25
Study 12638394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after high-fat breakfast
Number of subjects: 25
Study 12638394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg on empty stomach in the evening
Number of subjects: 25
Study 12638394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after moderate-fat meal in the evening
Number of subjects: 25
Study 10879639 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg bid on the 1st day, followed by 500 mg once daily for the next 4 days)
Number of subjects: 48
Study 10879639 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg bid for 14 days)
Number of subjects: 48
Study 10879639 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 48
Study 10879639 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 48
Study 8638462 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V/MPA
Number of subjects: 51
Study 8638462 — intervention group
Group type: COMPARATOR
Intervention: CE/MED
Number of subjects: 51
Study 1378136 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg b.i.d.)
Number of subjects: 31
Study 1378136 — intervention group
Group type: COMPARATOR
Intervention: Propranolol-ISDN (80 mg/20 mg b.i.d.)
Number of subjects: 31
Study 6089614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6089614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0
Study 6089614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31659977 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nails
Number of subjects: 98
Study 28555251 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein supplement (SUPP)
Number of subjects: 10
Study 26086284 — intervention group
Group type: EXPERIMENTAL
Intervention: Translaryngeal injection (TLI) technique
Number of subjects: 120
Study 26086284 — intervention group
Group type: COMPARATOR
Intervention: Enk Fibreoptic Atomizer
Number of subjects: 120
Study 23499273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels in the highest quartile
Number of subjects: 423
Study 23499273 — intervention group
Group type: COMPARATOR
Intervention: Cystatin C levels in the lower 3 quartiles
Number of subjects: 423
Study 21584955 — intervention group
Group type: EXPERIMENTAL
Intervention: Alflutop (intramuscular injections) + peloid applications
Number of subjects: 94
Study 19122088 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal backing of the tibial component
Number of subjects: 2352
Study 19122088 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 2352
Study 19122088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing
Number of subjects: 2352
Study 19122088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (overall)
Number of subjects: 2352
Study 16715016 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic examination
Number of subjects: 150
Study 14676530 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment of number of cortices
Number of subjects: 42